

## ISOGENICA ANNOUNCES DEPLOYMENT OF THE PIPEBIO BIOINFORMATIC CLOUD

Cambridge, UK. September 9<sup>th</sup>, 2021

Isogenica today announce that they are deploying PipeBio's Bioinformatics cloud to accelerate their drug discovery programmes in the field of therapeutic antibodies.

Simon Cooper, Isogenica Senior scientist II said, "For Isogenica one of the great strengths of the PipeBio platform is the ease with which we can rapidly characterise our synthetic antibody libraries, as well as associate functional data to deep sequencing data from selection outputs. The PipeBio platform allows us to truly leverage the power of our synthetic antibody library platform, NGS and rigorous biophysical analysis to produce developable lead candidates, faster."

"We are deeply inspired by the team at Isogenica and very excited to be entering into this collaboration, allowing the adoption of the PipeBio Bioinformatics cloud for analysis of Isogenica's innovative synthetic VHH antibody libraries. The library produces single domain VHH antibodies that can deliver important new biotherapeutics and we are proud to contribute. ***The intuitive nature of the bioinformatics platform and PipeBio's hands-on approach to development means the platform's functionality integrates seamlessly with our current approaches.***" Jannick Bendtsen, CEO of PipeBio.

The integration of PipeBio's analysis platform will accelerate the development of VHH discovery programs, correlating sequences with functional data - enhancing the discovery of developable VHH antibodies.

### About Isogenica

Isogenica specialises in single-domain biotherapeutics (VHH antibodies).

In collaboration with biopharmaceutical partners Isogenica has developed a deep pipeline including two clinical assets and numerous partnered discovery and pre-clinical stage programs.

Isogenica's library is fully synthetic, providing a key advantage that VHH are generated to specific epitopes which are difficult to target using conventional immunisation methods. Isogenica's library can be displayed in phage or in the company's proprietary CIS Display technology. Using our proprietary platform and technology, we deliver therapeutic antibodies that meet the highest standards of quality and developability. Isogenica's team specialise in discovery projects from target QC to Candidate selection.

VHH represent an ideal format for incorporation in CAR-T, T-cell engaging therapeutics, Antibody Radio Conjugates, Antibody Drug Conjugates and bispecific and multispecific formats. These antibodies are developed to a target product profile with carefully designed affinities, valencies and specificities enabling refined tumour cell targeting and modes of action.

**For more information:**Visit: [www.isogenica.com](http://www.isogenica.com) Contact: Mandeep Sehmi, Associate Director MarketingT: +44 1799 533 680 E: [mandeep.sehmi@isogenica.com](mailto:mandeep.sehmi@isogenica.com)**About PipeBio**

PipeBio is a cloud-based bioinformatics suite currently experiencing rapid growth throughout Europe and the Americas. Teams in pharma, biotechs and academia use PipeBio to rapidly-characterise and develop better lead candidates, faster. The strength of PipeBio is its unique ability to make structured sequence and assay data easily accessible to scientists, bioinformaticians and managers, combined with an ever growing suite of powerful analysis tools.

**For more information:**

Jannick Bendtsen

[jannick@pipebio.com](mailto:jannick@pipebio.com)

+45 5120 9694

**Press / media kit**[Click here to access PipeBio's Press kit](#)